Skip to main content
SpringerLink
Log in

Moderne Therapiestrategien bei hirneigenen glialen Tumoren

Gliome

  • zertifizierte fortbildung
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

Zusammenfassung

Die Kombination von Radio- und Chemotherapie kann das Gesamtüberleben von Patienten mit Gliomen signifikant verbessern. Dabei stehen heute neben der lokalen Kontrolle vor allem auch die Erhaltung der Lebensqualität und der neurokognitiven Funktion im Langzeitverlauf im Vordergrund.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Pallud J, Mandonnet E, Deroulers C, Fontaine D, Badoual M, Capelle L, Guillet-May F, Page P, Peruzzi P, Jouanneau E, Frenay M, Cartalat-Carel S, Duffau H, Taillandier L; Club de Neuro-Oncologie de la Société Française de Neurochirurgie (SFNC); Association des Neuro-Oncologues d’Expression Française (ANOCEF). Pregnancy increases the growth rates of World Health Organization grade II gliomas. Ann Neurol 2010;67:398–404.

    PubMed  Google Scholar 

  2. Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification of tumours of the central nervous system. Lyon: IARC, 2007.

    Google Scholar 

  3. Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB et al. Gliomatosis cerebri. Molecular pathology and clinical course. Ann Neurol 2002;52:390–399.

    Article  PubMed  CAS  Google Scholar 

  4. Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenberger G, Weller M, Herrlinger U; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 2011;70:445–453.

    Article  PubMed  CAS  Google Scholar 

  5. Sanson M, Cartalat-Carel S, Taillibert S, et al. Initial chemotherapy in gliomatosis cerebri. Neurology 2004;63:270–275.

    Article  PubMed  CAS  Google Scholar 

  6. Wick W, Meisner C, Hentschel B, et al. IDH1 mutations determine the prognostic versus predictive value of MGMT promoter methylation in malignant gliomas. Neurology, akzeptiert.

  7. Weller M, Stupp R, Reifenberger G et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6:39–51

    Article  PubMed  CAS  Google Scholar 

  8. Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing in malignant glioma patients in clinical practice. Neuro-Oncology 2012; 14: iv100–108.

    Google Scholar 

  9. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–773

    Article  PubMed  CAS  Google Scholar 

  10. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astroctytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707–718.

    Article  PubMed  Google Scholar 

  11. Macdonald DR, Cascino TL, Schold SC, Jr. et al. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280.

    PubMed  CAS  Google Scholar 

  12. Wen PY, Macdonald DR, Reardon DA et al. (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972.

    Article  PubMed  Google Scholar 

  13. Scott JN et al: How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59:947–949, 2002

    Article  PubMed  CAS  Google Scholar 

  14. Grant R, Liang BC, Slattery J, Greenberg HS, Junck L. Chemotherapy response criteria in malignant glioma. Neurology 1997;48:1336–1340.

    Article  PubMed  CAS  Google Scholar 

  15. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedan HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:143–151.

    Article  PubMed  CAS  Google Scholar 

  16. Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol 2012;13:e196–204.

    Article  Google Scholar 

  17. Rachinger W, Goetz C, Popperl G, Gildehaus FJ, Kreth FW, Holtmannspotter M, Herms J, Koch W, Tatsch K, Tonn JC. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005;57:505–511.

    Article  PubMed  Google Scholar 

  18. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 2011;13:307–316.

    Article  PubMed  CAS  Google Scholar 

  19. Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Göbel G, la Fougére C, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol 2013;15:341–351.

    Article  PubMed  CAS  Google Scholar 

  20. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392–401.

    Article  PubMed  CAS  Google Scholar 

  21. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforma: identification of and adjustment for bias. Neurosurgery 2008;62:564–576.

    Article  PubMed  Google Scholar 

  22. Stummer W, Nestler U, Stockhammer F, et al. Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. J Neurooncol im Druck.

  23. Kreth FW, Thon N, Siefert A, Tonn JC. The place of interstitial brachytherapy and radiosurgery for low-grade gliomas. Adv Tech Stand Neurosurg. 2010;35:183–212.

    Article  PubMed  CAS  Google Scholar 

  24. Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 2005;23:8863–8869.

    Article  PubMed  Google Scholar 

  25. Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 2010;28:3048–3053.

    Article  PubMed  Google Scholar 

  26. Wick W, Debus J, Bendszus M, Kobyakov G, Martens T, Heese O, Pichler J, Combs SE, Kunz C, Fricke H. A phase II, randomized open-label, multi-center study of weekls APG101 + reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma. ESMO/ECCO Abstract 3304, 2013.

    Google Scholar 

  27. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006;65:988–994

    Article  PubMed  Google Scholar 

  28. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852–9861

    Article  PubMed  CAS  Google Scholar 

  29. Van den Bent M, Brandes AA, Taphoorn M, et al. Adjuvant procarbacine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol 2012; 31: 344–350.

    Article  PubMed  Google Scholar 

  30. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2012; 31: 337–343.

    Article  PubMed  Google Scholar 

  31. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol 2009a;27:5874–5880.

    Article  PubMed  CAS  Google Scholar 

  32. Stupp R, Mason WP, Van Den Bent MJ et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine 352:987–996.

    Article  PubMed  CAS  Google Scholar 

  33. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and response to temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.

    Article  PubMed  CAS  Google Scholar 

  34. Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012 Jul;13(7):707–715.

    Article  PubMed  CAS  Google Scholar 

  35. Malmström A, Grønberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012 Sep;13(9):916–926.

    Article  PubMed  Google Scholar 

  36. Soffietti R et al: Guidelines on management of low-grade gliomas: report of an EFNS-EANO* task force. Eur J Neurol 17:1124–1133, 2010

    Article  PubMed  CAS  Google Scholar 

  37. Weiler M, Wick W. Molecular predictors of outcome in low-grade glioma. Current Opinion in Neurology 2012;25:767–773.

    Article  PubMed  Google Scholar 

  38. Wick W, Weller M, Weiler M, Batchelor T, Yung AWK, Platten M: Pathway inhibition: Emerging molecular targets for treating glioblastoma. Neuro Oncol 13:566–579, 2011

    Article  PubMed  CAS  Google Scholar 

  39. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro Oncol 2013;15:4–27.

    Article  PubMed  Google Scholar 

  40. Wick W, Weller M, Van Den Bent M et al. (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 28:e188–189; author reply e190-182.

    Article  Google Scholar 

  41. Friedman H, Prados M, Wen P, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733–4740.

    Article  PubMed  CAS  Google Scholar 

  42. Amberger-Murphy V. Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 2009;9:381–390.

    Article  PubMed  CAS  Google Scholar 

  43. Harris AL. Hypoxia: a key regulatory factor in tumor growth. Nat Rev Cancer. 2002;2:38-

    Article  PubMed  CAS  Google Scholar 

  44. Wick W, Cloughesy TF, Nishikawa R, et al: Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). 2013 ASCO Annual Meeting. Abstract 2002. Presented June 1, 2013.

    Google Scholar 

  45. Roth P et al: Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol 23:597–602, 2010

    Article  PubMed  CAS  Google Scholar 

  46. Weller M, Stupp R, Wick W. Epilepsy meets Cancer: when, why, and what to do about it? Lancet Oncol 2012;13:e375–382

    Article  Google Scholar 

  47. Wick W, Menn O, Meisner C, et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 2005;28:391–396.

    Article  PubMed  CAS  Google Scholar 

  48. Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJ. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360:1361–1368.

    Article  PubMed  CAS  Google Scholar 

  49. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer 2000;89:640–646.

    Article  PubMed  CAS  Google Scholar 

  50. Perry JR et al: PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 8:1959–1965, 2008

    Article  Google Scholar 

  51. Schmidt F, Faul C, Dichgans J, et al. Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol 2002;249:1409–1412.

    Article  PubMed  CAS  Google Scholar 

  52. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356:1527–1535.

    Article  PubMed  CAS  Google Scholar 

  53. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22:1583–1588.

    Article  PubMed  CAS  Google Scholar 

  54. Wiestler B, Claus R, Hartlieb SA et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol. 2013 Apr 17. [Epub ahead of print]

    Google Scholar 

  55. Harrison, Deutsche Auflage 2012; Kapitel 379, Hirneigene Tumoren und Metastasen

    Google Scholar 

  56. Bendszus & Platten, Neuroradiologische Responsekriterien bei malignen Gliomen, Nervenarzt 2011

  57. Pignatti F, van den Bent, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20:2076–2084

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Neuroonkologie, Universitätsklinik Heidelberg Deutsches Konsortium für Translationale Krebsforschung (DKTK), Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland

    Wolfgang Wick &  Michael Platten

Authors
  1. Wolfgang Wick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Platten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Wick.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließen. Prof. Wick erhält Forschungsunterstützung von Apogenix, Boehringer Ingelheim, Eli Lilly, MSD und Roche. Er hat außerdem persönliche Vortragshonorare von MSD und Roche erhalten. Er ist Mitglied des Steering Committees der AVAglio-Studie und von Advisory Boards der Formen MSD, Magforce und Roche/Genentech. Er ist außerdem Studienleiter der EORTC-26101- und 26082-Studien und der APG101 sowie Sprecher der Hirntumorgruppe der EORTC und stellvertretender Sprecher der NOA.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME- Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wick, W., Platten, M. Moderne Therapiestrategien bei hirneigenen glialen Tumoren. InFo Neurologie 15, 38–51 (2013). https://doi.org/10.1007/s15005-013-0305-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-013-0305-1

Search

Navigation